Overdiagnosis of invasive breast cancer in population-based breast cancer screening: A short- and long-term perspective
- PMID: 35839596
- DOI: 10.1016/j.ejca.2022.06.027
Overdiagnosis of invasive breast cancer in population-based breast cancer screening: A short- and long-term perspective
Abstract
Background: Overdiagnosis of invasive breast cancer (BC) is a contentious issue.
Objective: The aim of this paper is to estimate the overdiagnosis rate of invasive BC in an organised BC screening program and to evaluate the impact of age and follow-up time.
Methods: The micro-simulation model SiMRiSc was calibrated and validated for BC screening in Flanders, where women are screened biennially from age 50 to 69. Overdiagnosis rate was defined as the number of invasive BC that would not have been diagnosed in the absence of screening per 100,000 screened women during the screening period plus follow-up time (which was set at 5 years and varied from 2 to 15 years). Overdiagnosis rate was calculated overall and stratified by age.
Results: The overall overdiagnosis rate for women screened biennially from 50 to 69 was 20.1 (95%CI: 16.9-23.2) per 100,000 women screened at 5-year follow-up from stopping screening. Overdiagnosis at 5-year follow-up time was 12.9 (95%CI: 4.6-21.1) and 74.2 (95%CI: 50.9-97.5) per 100,000 women screened for women who started screening at age 50 and 68, respectively. At 2- and 15-year follow-up time, overdiagnosis rate was 98.5 (95%CI: 75.8-121.3) and 13.4 (95%CI: 4.9-21.9), respectively, for women starting at age 50, and 297.0 (95%CI: 264.5-329.4) and 34.2 (95%CI: 17.5-50.8), respectively, for those starting at age 68.
Conclusions: Sufficient follow-up time (≥10 years) after screening stops is key to obtaining unbiased estimates of overdiagnosis. Overdiagnosis of invasive BC is a larger problem in older compared to younger women.
Keywords: Breast neoplasms; Invasive breast cancer; Mammography; Mass screening; Modelling studies; Overdiagnosis.
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Comment in
-
What a woman needs to know about overdiagnosis to decide about breast cancer screening.Eur J Cancer. 2022 Sep;173:327-328. doi: 10.1016/j.ejca.2022.06.056. Epub 2022 Aug 5. Eur J Cancer. 2022. PMID: 35941030 No abstract available.
Similar articles
-
Incidence of breast cancer and estimates of overdiagnosis after the initiation of a population-based mammography screening program.CMAJ. 2013 Jul 9;185(10):E492-8. doi: 10.1503/cmaj.121791. Epub 2013 Jun 10. CMAJ. 2013. PMID: 23754101 Free PMC article.
-
Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up.Breast Cancer Res. 2018 Dec 17;20(1):153. doi: 10.1186/s13058-018-1082-z. Breast Cancer Res. 2018. PMID: 30558679 Free PMC article.
-
Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States.Ann Intern Med. 2023 Sep;176(9):1172-1180. doi: 10.7326/M23-0133. Epub 2023 Aug 8. Ann Intern Med. 2023. PMID: 37549389 Free PMC article.
-
Interpreting overdiagnosis estimates in population-based mammography screening.Epidemiol Rev. 2011;33(1):111-21. doi: 10.1093/epirev/mxr009. Epub 2011 Jun 27. Epidemiol Rev. 2011. PMID: 21709144 Free PMC article. Review.
-
Mammographic screening for breast cancer. Overdiagnosis: an insidious adverse effect of screening.Prescrire Int. 2015 Jul;24(162):186-9, 191. Prescrire Int. 2015. PMID: 26240891 Review.
Cited by
-
Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment.Med Oncol. 2023 Jul 14;40(8):238. doi: 10.1007/s12032-023-02111-9. Med Oncol. 2023. PMID: 37442848 Review.
-
The Impact of Organised Screening Programs on Breast Cancer Stage at Diagnosis for Canadian Women Aged 40-49 and 50-59.Curr Oncol. 2022 Aug 9;29(8):5627-5643. doi: 10.3390/curroncol29080444. Curr Oncol. 2022. PMID: 36005182 Free PMC article.
-
Thirty years of population-based breast cancer screening in Iceland: a comparison of quality indicators and tumour characteristics between women aged 40-49 and 50-69 years.Acta Oncol. 2025 Aug 14;64:1061-1070. doi: 10.2340/1651-226X.2025.44090. Acta Oncol. 2025. PMID: 40814243 Free PMC article.
-
Impact of Breast Cancer Screening on 10-Year Net Survival in Canadian Women Age 40-49 Years.J Clin Oncol. 2023 Oct 10;41(29):4669-4677. doi: 10.1200/JCO.23.00348. Epub 2023 Aug 4. J Clin Oncol. 2023. PMID: 37540825 Free PMC article.
-
Overdiagnosis Due to Screening Mammography for Breast Cancer among Women Aged 40 Years and Over: A Systematic Review and Meta-Analysis.J Pers Med. 2023 Mar 14;13(3):523. doi: 10.3390/jpm13030523. J Pers Med. 2023. PMID: 36983705 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical